KR20010057591A - 알로페론-면역조절펩티드 - Google Patents
알로페론-면역조절펩티드 Download PDFInfo
- Publication number
- KR20010057591A KR20010057591A KR1020000082812A KR20000082812A KR20010057591A KR 20010057591 A KR20010057591 A KR 20010057591A KR 1020000082812 A KR1020000082812 A KR 1020000082812A KR 20000082812 A KR20000082812 A KR 20000082812A KR 20010057591 A KR20010057591 A KR 20010057591A
- Authority
- KR
- South Korea
- Prior art keywords
- gly
- val
- ser
- gln
- ala
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims abstract description 5
- 102000014150 Interferons Human genes 0.000 claims description 94
- 108010050904 Interferons Proteins 0.000 claims description 94
- 229940079322 interferon Drugs 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000001472 cytotoxic effect Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 210000004698 lymphocyte Anatomy 0.000 claims description 26
- 230000000840 anti-viral effect Effects 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 claims 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108010078274 isoleucylvaline Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 108010019182 Alloferon Proteins 0.000 abstract description 56
- 230000000694 effects Effects 0.000 abstract description 45
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 241000700605 Viruses Species 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 241000588724 Escherichia coli Species 0.000 abstract description 4
- 241000191938 Micrococcus luteus Species 0.000 abstract description 2
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 210000002751 lymph Anatomy 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000005965 immune activity Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 24
- 230000003013 cytotoxicity Effects 0.000 description 23
- 231100000135 cytotoxicity Toxicity 0.000 description 23
- 108010036413 histidylglycine Proteins 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 16
- 102100040018 Interferon alpha-2 Human genes 0.000 description 15
- 108010079944 Interferon-alpha2b Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000000822 natural killer cell Anatomy 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 101710113252 Alloferon-1 Proteins 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 9
- FQMLTEAEJZVTAJ-UHFFFAOYSA-M sodium;2-(9-oxoacridin-10-yl)acetate Chemical compound [Na+].C1=CC=C2N(CC(=O)[O-])C3=CC=CC=C3C(=O)C2=C1 FQMLTEAEJZVTAJ-UHFFFAOYSA-M 0.000 description 9
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 8
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229960000888 rimantadine Drugs 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 241001500350 Influenzavirus B Species 0.000 description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 7
- 229960000329 ribavirin Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011287 therapeutic dose Methods 0.000 description 7
- 241001500351 Influenzavirus A Species 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000002799 interferon inducing agent Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- BLAHYQDPBVTOGJ-OKFWTXGRSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 BLAHYQDPBVTOGJ-OKFWTXGRSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010026422 allostatin-1 Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 241000257163 Calliphora vicina Species 0.000 description 3
- VOCMRCVMAPSSAL-IUCAKERBSA-N Gly-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN VOCMRCVMAPSSAL-IUCAKERBSA-N 0.000 description 3
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000007665 chronic toxicity Effects 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 101800003908 Alloferon-2 Proteins 0.000 description 2
- 101710185173 Arylphorin Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 2
- CHZRWFUGWRTUOD-IUCAKERBSA-N His-Gly-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N CHZRWFUGWRTUOD-IUCAKERBSA-N 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YZUWGFXVVZQJEI-PMVVWTBXSA-N Thr-Gly-His Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O YZUWGFXVVZQJEI-PMVVWTBXSA-N 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000001779 embryotoxic effect Effects 0.000 description 2
- 231100000238 embryotoxicity Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- FLYANDHDFRGGTM-PYJNHQTQSA-N Arg-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FLYANDHDFRGGTM-PYJNHQTQSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- ZSVJVIOVABDTTL-YUMQZZPRSA-N Asp-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N ZSVJVIOVABDTTL-YUMQZZPRSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000257160 Calliphora Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- NROSLUJMIQGFKS-IUCAKERBSA-N Gln-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N NROSLUJMIQGFKS-IUCAKERBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- DUYYPIRFTLOAJQ-YUMQZZPRSA-N Gly-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN DUYYPIRFTLOAJQ-YUMQZZPRSA-N 0.000 description 1
- LLXVQPKEQQCISF-YUMQZZPRSA-N Gly-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN LLXVQPKEQQCISF-YUMQZZPRSA-N 0.000 description 1
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 1
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 description 1
- DNVDEMWIYLVIQU-RCOVLWMOSA-N Gly-Val-Asp Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O DNVDEMWIYLVIQU-RCOVLWMOSA-N 0.000 description 1
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- OEROYDLRVAYIMQ-YUMQZZPRSA-N His-Gly-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O OEROYDLRVAYIMQ-YUMQZZPRSA-N 0.000 description 1
- FZKFYOXDVWDELO-KBPBESRZSA-N His-Gly-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FZKFYOXDVWDELO-KBPBESRZSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000909835 Hyalophora gloveri Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241000258916 Leptinotarsa decemlineata Species 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 244000090896 Nigella sativa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- RORUIHAWOLADSH-HJWJTTGWSA-N Phe-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 RORUIHAWOLADSH-HJWJTTGWSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- DWUIECHTAMYEFL-XVYDVKMFSA-N Ser-Ala-His Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 DWUIECHTAMYEFL-XVYDVKMFSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000254109 Tenebrio molitor Species 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- FMQGYTMERWBMSI-HJWJTTGWSA-N Val-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N FMQGYTMERWBMSI-HJWJTTGWSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical class C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
펩티드 | 위치 | |||||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | |
알로페론 1 | His | Gly | Val | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | His | Gly | - |
알로페론 2 | - | Gly | Val | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | His | Gly | - |
알로페론 3 | - | - | Val | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | His | - | - |
알로페론 4 | - | - | - | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | - | ||
알로페론 5 | Pro | Ser | Leu | Thr | Gly | His | Gly | - | Phe | - | His | Gly | Val | Tyr | Asp | - |
알로페론 6 | Phe | Ile | Val | Ser | Ala | His | Gly | - | Asp | - | His | Gly | Val | - | - | - |
알로페론 7 | - | - | - | - | Thr | His | Gly | - | Gln | - | His | Gly | Val | - | - | - |
알로페론 8 | - | - | - | - | - | His | Gly | - | - | - | His | Gly | Val | His | Gly | - |
알로페론 9 | - | Leu | Ala | Ser | Leu | His | Gly | - | Gln | - | His | Gly | Val | - | - | - |
알로페론 10 | Cys | Val | Val | Thr | Gly | His | Gly | - | Ser | - | His | Gly | Val | Phe | Val | - |
알로페론 11 | - | - | Ile | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | Pro | - | - |
알로페론 12 | - | - | - | Cys | Gly | His | Gly | - | Asn | - | His | Gly | Val | His | - | - |
알로페론 13 | Ile | Val | Ala | Arg | Ile | His | Gly | - | Gln | Asn | His | Gly | Val | - | - | - |
알로페론 14 | - | - | - | - | - | His | Gly | Ser | Asp | Gly | His | Gly | Val | Gln | His | Gly |
알로페론 15 | - | - | - | Phe | Gly | His | Gly | - | - | - | His | Gly | Val | - | - | - |
알로페론 16 | - | - | - | - | - | His | Gly | - | Asn | - | His | Gly | Val | Leu | Ala | - |
알로페론 17 | His | Gly | Asp | Ser | Gly | His | Gly | - | Gln | - | His | Gly | Val | Asp | - | - |
알로페론 18 | - | - | - | - | - | His | Gly | - | - | - | His | Gly | Val | Pro | Leu | - |
알로페론 19 | - | - | - | Ser | Gly | His | Gly | - | Ala | Val | His | Gly | Val | Met | - | - |
알로페론 20 | Tyr | Ala | Met | Ser | Gly | His | Gly | - | - | - | His | Gly | Val | Phe | Ile | - |
인플루엔자바이러스 B 전구체(377-387) | His | Gly | Tyr | Thr | Ser | His | Gly | Ala | His | Gly | Val | |||||
일반식(1) | X1 | His | Gly | X2 | His | Gly | Val | X3 |
활성 | in vivo(mg/kg body mass) 또는in vitro(ng/ml) 유효 농도 | 의학적 용도 |
생쥐 비장 림프구의 세포독성 활성촉진 | 0.05-50ng/ml | 감염성 및 종양성 질병의 치료 |
인플루엔자 바이러스 A 감염에 대한 생쥐의 저항성 촉진 | 1.25mg/kg | 인플루엔자 치료 |
인플루엔자 바이러스 B 감염에 대한 생쥐의 저항성 촉진 | 1.25mg/kg | 인플루엔자 치료 |
생쥐에서 인터페론 합성 유도 | 0.125-1.25mg/kg | 바이러스 및 종양성 질병 치료 |
인간 말초혈액 림프구의 세포독성활성촉진 | 0.0005-500ng/ml | 바이러스 및 종양성 질병 치료 |
암환자에서 말초혈액 림프구의 세포독성활성촉진 | 5ng/ml | 암의 아쥬반트 치료 |
처리 | 농도(ng/ml) | 세포독성지수 | |
평균, %(n=18) | % to control | ||
대조군 | 0 | 21.3±3.0 | 100 |
알로페론 | 0.050.5550500 | 35.2±4.0**39.3±3.9***34.3±4.5**37.2±4.5**20.3±3.6 | 16518516117595 |
처리 | 농도(ng/ml) | 세포독성지수 | |
% | % to control | ||
대조군 | 0 | 27.3±7.3 | 100 |
인터페론-알파 2b | 5 | 64.3±3.8 | 236*** |
알로페론 | 0.00050.0050.050.5550500 | 62.0±6.573.8±1.779.8±5.079.8±2.866.8±7.268.0±5.368.8±4.4 | 227***270***292***292***245***249***252*** |
번호 | 조제물 | 세포독성지수M±m, % | 통계적으로 유의성이 있는 촉진(P≤0.05) | ||
K562 | A431 | K562 | A431 | ||
1 | 대조군인터페론알로페론 | 5.3±4.450.2±1.6***30.2±5.5** | 53.8±6.555.7±8.683.7±2.9** | ++ | -+ |
2 | 대조군인터페론알로페론 | 14.2±3.350.2±2.5***39.8±1.5*** | -64.5±40.6-88.3±40.4-86.7±22.8 | ++ | -- |
3 | 대조군인터페론알로페론 | 29.8±7.421.8±7.530.8±6.8 | -53.6±19.927.0±6.5**39.7±3.3*** | -- | ++ |
4 | 대조군인터페론알로페론 | 30.0±2.942.8±2.4**45.4±2.3*** | 83.8±3.689.5±2.391.2±0.9 | ++ | -- |
5 | 대조군인터페론알로페론 | 43.3±3.564.2±5.7***51.0±1.7 | -14.8±8.335.4±5.2***24.4±4.0** | +- | ++ |
6 | 대조군인터페론알로페론 | 41.7±10.530.5±8.637.6±10.2 | 50.0±5.743.7±5.053.7±4.4 | -- | -- |
7 | 대조군인터페론알로페론 | 40.3±3.258.2±2.5**59.2±5.2** | 17.3±5.511.8±8.3-10.2±8.0 | ++ | -- |
8 | 대조군인터페론알로페론 | 23.0±3.519.2±2.329.2±6.3 | -20.0±6.374.0±2.7***80.7±1.8*** | -- | ++ |
9 | 대조군인터페론알로페론 | 6.2±11.325.0±4.625.0±12.3 | 7.8±15.638.5±3.424.5±15.1 | -- | _- |
10 | 대조군인터페론알로페론 | 34.3±1.351.8±2.9**44.8±3.5* | 74.0±4.582.7±1.988.4±1.2** | ++ | -+ |
11 | 대조군인터페론알로페론 | 57.0±4.452.0±2.242.8±5.9 | 37.2±6.750.8±9.246.5±7.6 | -- | -- |
12 | 대조군인터페론알로페론 | 61.8±3.471.8±2.9*47.8±4.1 | 55.6±4.951.4±3.656.4±3.1 | +- | -- |
13 | 대조군인터페론알로페론 | 44.0±13.162.7±7.549.7±3.9 | 52.8±6.558.2±6.154.8±4.0 | -- | -- |
14 | 대조군인터페론알로페론 | 30.2±6.114.7±8.72.0±4.2 | -6.0±8.148.7±4.5**49.8±12.9** | -- | ++ |
15 | 대조군인터페론알로페론 | 16.8±2.32.2±3.819.5±6.8 | 11.2±6.825.0±5.727.7±3.7 | -- | -- |
16 | 대조군인터페론알로페론 | -3.5±7.45.0±4.718.5±1.7* | 61.4±7.169.2±2.168.7±2.0 | -+ | -- |
17 | 대조군인터페론알로페론 | 23.3±5.629.0±3.324.7±4.0 | 57.8±4.162.5±1.764.3±4.1 | -- | -- |
Indicator | 인터페론 | 알로페론 |
제공자의 수 | 17 | |
양성반응비율:K562A431K562 또는A431 | 7/17=41%4/17=24%10/17=59% | 6/17=35%6/17=35%10/17=59% |
양성반응 일치:인터페론, 알로페론 모두 민감인터페론에만 민감알로페론에만 민감 | 9/17=63%1/17=6%1/17=6% |
번호 | 진단 | 처리 | 세포독성지수,% | 통계적으로 유의성이 있는 촉진(P≤0.05) | ||
K562 | A431 | K562 | A431 | |||
1 | 만성leucosis | 대조군인터페론알로페론 | 11.2±10.6-5.5±7.9-35.3±5.4 | -4.2±8.711.7±12.5-9.0±12.7 | -- | -- |
2 | 만성leucosis | 대조군인터페론알로페론 | 4.8±5.4-10.7±4.91.3±2.3 | 37.0±5.633.3±9.08.2±8.3 | -- | -- |
3 | 만성leucosis | 대조군인터페론알로페론 | -8.3±2.3-3.5±4.0-12.8±3.7 | -16.2±10.633.5±7.4**26.2±3.8** | -- | ++ |
4 | 만성leucosis | 대조군인터페론알로페론 | -11.0±3.6-9.2±7.0-1.5±5.1 | 28.2±5.918.8±4.319.2±6.3 | -- | -- |
5 | 만성leucosis | 대조군인터페론알로페론 | -23.0±5.3-4.6±9.6-8.0±18.8 | 15.2±8.346.0±4.0**42.5±3.9** | -- | ++ |
6 | 급성leucosis | 대조군인터페론알로페론 | 42.3±2.725.2±4.0**20.2±6.8** | 6.2±16.543.5±6.4*48.5±13.5* | -- | ++ |
7 | 급성leucosis | 대조군인터페론알로페론 | 29.2±5.650.2±2.3**28.2±2.6 | -18.7±14.624.8±10.1*20.0±6.9* | +- | ++ |
8 | 급성leucosis | 대조군인터페론알로페론 | 15.2±9.440.0±3.4**23.5±5.5 | 25.2±6.517.8±8.340.4±6.2 | +_ | -- |
9 | 급성leucosis | 대조군인터페론알로페론 | 23.5±8.225.1±4.613.8±4.4 | -4.8±9.051.5±6.5***51.8±4.8*** | -- | ++ |
10 | 폐암 | 대조군인터페론알로페론 | 11.5±3.727.2±4.2**-0.3±6.1 | -7.2±10.259.5±3.9***55.5±2.7*** | +- | ++ |
11 | 자궁암 | 대조군인터페론알로페론 | 30.5±1.350.8±4.9***24.0±4.4 | 93.3±1.093.5±0.994.3±0.4 | +- | -- |
12 | Hodgkin lymphoma | 대조군인터페론알로페론 | 22.2±8.739.3±4.927.7±4.8 | 90.3±0.9595.2±0.79**90.2±0.47 | -- | +- |
13 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 11.5±6.413.8±3.017.7±2.8 | 82.8±1.180.2±2.091.5±0.8*** | -- | -+ |
14 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 16.3±9.631.2±9.236.7±9.1 | -40.0±20.526.0±8.9**15.3±4.8** | -- | ++ |
15 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 19.2±12.147.5±6.6*37.3±4.7 | 57.7±4.462.2±5.264.0±5.0 | +- | -- |
16 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 35.8±8.343.2±3.537.3±7.0 | 47.2±10.443.5±4.456.3±4.4 | -- | -- |
17 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 49.4±3.248.8±3.568.3±4.6** | 66.7±6.267.0±3.364.3±5.1 | -+ | -- |
18 | Non-Hodgkin lymphoma | 대조군인터페론알로페론 | 6.3±14.9-3.0±8.7-10.7±14.1 | 29.8±4.633.2±7.432.8±9.2 | -- | -- |
Indicator | 인터페론 | 알로페론 |
제공자의 수 | 18 | |
양성반응비율:K562A431K562 또는A431 | 6/18=33%8/18=44%10/18=56% | 1/18=6%8/18=44%9/18=50% |
양성반응 일치:인터페론, 알로페론 모두 민감인터페론에만 민감알로페론에만 민감 | 7/18=38%4/18=22%2/18=11% |
조제물 | 실험횟수 | 평균세포독성지수M±m, % | P |
대조군 | 6 | -6.0±8.1 | |
인터페론 | 6 | 48.7±4.6 | <0.001 |
알로페론 1 | 4 | 49.8±12.8 | <0.01 |
알로페론 3 | 6 | 60.2±2.7 | <0.001 |
알로페론 4 | 5 | 60.8±2.4 | <0.001 |
처리 | 투여용량μg per mouse | 실험동물수 | 바이러스 주입후 10일간 사망률 | |
사망한 동물수 | % | |||
대조군 | - | 20 | 14 | 70 |
알로페론 | 2.5 | 20 | 13 | 65 |
알로페론 | 25 | 20 | 5 | 25* |
처리 | 투여용량μg per mouse | 실험동물수 | 바이러스 주입후 10일간 사망률 | |
사망한 동물수 | % | |||
대조군 | - | 20 | 13 | 65 |
알로페론 | 25 | 18 | 4 | 22* |
리만타딘 | 1000 | 19 | 1 | 5*** |
처리 | 바이러스 투여용량(LD50equivalents) | 동물 마리수 | 바이러스 주입 후 10일간 사망률 | |
Number | % | |||
대조군 | 303 | 1310 | 108 | 7780 |
리바비린, 250μg | 303 | 1010 | 60 | 600*** |
알로페론, 25μg | 303 | 1010 | 20 | 20***0*** |
처리 | 시간 | 동물마리수 | 실험횟수 | 인터페론 타이터(유닛) |
대조군 | 8 | 15±5 | ||
사이클로페론,500μg | 424 | 88 | 22 | 95±4549±3.8* |
알로페론25μg | 2424 | 888 | 222 | 31±13.821±3.771±16.2* |
처리 | 시간(hour) | 동물마리수 | 인터페론 역가(유닛) |
대조군 | 7 | 7.1±1.8 | |
사이클로페론,500μg | 624 | 77 | 32.9±10.7*11.4±2.8 |
알로페론25μg | 624 | 88 | 40.6±11.4*14.4±4.3 |
활성 | 방법 | 결과 | 결론 |
급성독성 | 생쥐에서 500-6000mg/kg 및 랫트에서 300-5000mg/kg의 농도로 피하 및 위장내 단회투여 | 가장 높은 투여용량을 포함한 어떠한 용량에서도 사망이 기록되지 않았다. 동물의 성장, 급식, 뇌의 육안구조, 주입부위의 피부 및 피하조직뿐만 아니라 내분비기관의 어떠한 변화도 모든 투여용량에서 발견되지 않았다. | 독성측정자료는 양성임. 독성/치료 용량의 비는 랫트에서 >35700배이고 생쥐에서 >42800배이다. |
아급성 및 만성독성기니아 피그에서의 알러젠 활성 | 0.2, 2, 20mg/kg로 90일동안 하루에 한번 투여아나필락시스 쇼크면역복합반응지방세포(fat cell)탈과립화의 간접적 반응Conjunctive probe지연성과민증 반응 | 90일동안 한마리의 동물도 죽지 않았다. 동물의 성장, 급식, 직장의 온도, 검안(점막표면상태 및 눈의 형태), 신경정신(흥분한계치, 자발적 운동활성), 심혈관(심장수축기 동맥압, 심장박동률, 심전도), 간(hexenal sleep), 신장(오줌조성, 페놀 레드 분비), 혈액학적지수(hemogram, leukocyte formula, coagulogram), 말초혈액의 생화학적 지수(단백질, 요소, 크레아틴, 포도당, 지질, 콜레스테롤, 빌리루빈, 효소활성, 전해질 조성), 혈액형성지수, 병리학 및 조직학(심장, 폐, 기관지, 위, 이자, 상피조직, 흉선, 간, 비장, 신장, 부신, 뇌,정소, 난소)자료의 분석결과, 개체기능의 음성적 변화를 나타내지 않았다.치료용량에서 아나필락시스의 어떠한 징후도 나타나지 않았다. 단기간 불안, 코 긁기, 빠른 호흡과 같은 최소한의 반응이 치료용량의 10배로 투여한 12마리의 기니아 피그중 수컷 한 마리에서 기록되었다.알로페론의 치료용량 및 그것의 10배 투여시 어떠한 반응도 관찰되지 않았다.알로페론의 치료용량 및 그것의 10배 투여시지방세포 탈과립화율은 변화하지 않았다.알로페론의 치료용량 및 그것의 10배 투여시어떠한 반응도 관찰되지 않았다.알로페론의 치료용량 및 그것의 10배 투여시 어떠한 반응도 관찰되지 않았다. | 알로페론은 치료용량 및 치료용량의 10, 100 배 초과용량으로 장기간 랫 트에매일 투여하였을때 어떠한 독성효과도 가지지 않는다.알로페론은 검출될만한 알러젠 활성을 가지고 있지 않다. |
배아독성 및 생식기능에 대한 영향 | 1.5, 15mg/kg의 농도로 임신한 쥐에 피하주사 | 알로페론 투여는 암컷, 수컷의 생식기능 변화뿐만 아니라 자손에 있어서 태아 발생 및 신생과정에 있어 음성적 영향을 끼치지 않는다. | 알로페론은 랫트에서 생식활성에 대한 영향뿐만 아니라 독성활성을 가지고 있지 않다. |
돌연변이 유발성 | 생쥐 생식세포의 치명적 우성 돌연변이생쥐골수세포의 염색체변화Ames 시험DNA SOS 반응 | 15mg/kg의 용량에서 알로페론은 생쥐생식세포에 치명적인 우성돌연변이를 유도하지 않았다.알로페론은 0.5, 15mg/kg 및 0.5mg/kg의 5배 용량 단회투여에서 생쥐골수세포의 염색체변화를 유발하지 않았다.0.1-1000μg/petri dish의 농도범위에서 3회 측시험결과 알로페론은 살모넬라 티피무리움(Salmonella typhimurium)의 유전자변화를 유도하지 않았다.알로페론은 대장균 PQ37 균주에서 DNA 손상활성을 나타내지 않았다. | 알로페론은 돌연변이 유발성 및 강력한 발암성을 가지고 있지 않다. |
Claims (16)
- 하기 일반구조식 (1)을 가지며, 면역조절활성을 나타내는 것을 특징으로 하는 아미노산 잔기 30개까지로 구성되는 펩티드 또는 약학적으로 허용되는 그의 염(salt) 혹은 에테르(ether):X1-His-Gly-X2-His-Gly-Val-X3(1)상기 식에서,X1은 존재하지 않거나 또는 적어도 한 개의 아미노산 잔기를 나타내고,X2는 펩티드결합 또는 적어도 한 개의 아미노산 잔기를 나타내며,X3는 존재하지 않거나 또는 적어도 한 개의 아미노산 잔기를 나타낸다.
- 제 1항에 있어서,아미노산 잔기 20개까지로 구성되는펩티드.
- 제 1항 내지 제 2항 중 어느 한 항에 있어서,X2는 0 내지 3의 아미노산 잔기를 나타내는펩티드.
- 제 1항 내지 제 3항 중 어느 한 항에 있어서,X1은 아무것도 포함하지 않거나, His-Gly-Val-Ser-Gly-, Gly-Val-Ser-Gly-, Val-Ser-Gly-, Ser-Gly-, Pro-Ser-Leu-Thr-Gly-, Phe-Ile-Val-Ser-Ala-, Thr-, Leu-Ala-Ser-Leu-, Cys-Val-Val-Thr-Gly-, Ile-Ser-Gly-, Cys-Gly-, Ile-Val-Ala-Arg-Ile-, Phe-Gly-, His-Gly-Asp-Ser-Gly-, Ser-Gly- 및 Tyr-Ala-Met-Ser-Gly-으로 구성되는 그룹으로부터 선택되는펩티드.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서,X2는 펩티드 결합이거나, -Gln-, -Phe-, -Asp-, -Ser-, -Asn-, -Ala-,-Gln-Asn-, -Ala-Val- 및 -Ser-Asp-Gly-으로 구성되는 그룹으로부터 선택 되는펩티드.
- 제 1항 내지 제 5항 중 어느 한 항에 있어서,X3은 아무것도 포함하지 않거나, -His-Gly, -His, -Tyr-Asp, -Phe-Val, -Pro, -Gln-His-Gly, -Leu-Ala, -Asp, -Pro-Leu, -Met 및 -Phe-Ile으로 구성되는 그룹으로부터 선택되는펩티드.
- 제 1항에 있어서,His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly,Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly,Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His,Ser-Gly-His-Gly-Gln-His-Gly-Val,Pro-Ser-Leu-Thr-Gly-His-Gly-Phe-His-Gly-Val-Tyr-Asp,Phe-Ile-Val-Ser-Ala-His-Gly-Asp-His-Gly-Val,Thr-His-Gly-Gln-His-Gly-Val,His-Gly-His-Gly-Val-His-Gly,Leu-Ala-Ser-Leu-His-Gly-Gln-His-Gly-Val,Cys-Val-Val-Thr-Gly-His-Gly-Ser-His-Gly-Val-Phe-Val,Ile-Ser-Gly-His-Gly-Gln-His-Gly-Val-Pro,Cys-Gly-His-Gly-Asn-His-Gly-Val-His,Ile-Val-Ala-Arg-Ile-HIs-Gly-Gln-Asn-His-Gly-Val,His-Gly-Ser-Asp-Gly-His-Gly-Val-Gln-His-Gly,Phe-Gly-His-Gly-His-Gly-Val,His-Gly-Asn-His-Gly-Val-Leu-Ala,His-Gly-Asp-Ser-Gly-His-Gly-Gln-His-Gly-Val-Asp,His-Gly-His-Gly-Val-Pro-Leu,Ser-Gly-His-Gly-Ala-Val-His-Gly-Val-Met 및Tyr-Ala-Met-Ser-Gly-His-Gly-His-Gly-Val-Phe-Ile으로 구성되는 그룹으로부터 선택되는펩티드.
- 제 1항 내지 제 7항의 어느 한 항에 개시된 아미노산 서열, 또는 그것의 약학적으로 활성화된 염 또는 에테르를 포함하며 면역조절활성을 나타내는 합성화합물(단, 전기 화합물은 자연계에 존재하는 펩티드나 단백질이 아니다.).
- 제 1항 내지 제 7항의 어느 한 항에 개시된 펩티드, 제 8항에 개시된 화합물 또는 전기 펩티드 혹은 화합물의 약학적으로 활성화된 염 또는 에테르를 포함하는 약학적 조성물.
- 제 1항 내지 제 7항의 어느 한 항에 개시된 펩티드, 제 8항에 개시된 화합물 또는 전기펩티드 혹은 화합물의 약학적으로 활성화된 염 또는 에테르의 면역조절활성을 갖는 약학적 조성물의 조제를 위한 용도.
- 제 10항에 있어서,약학적 조성물은 인터페론 유발활성, 항바이러스 활성, 항암활성을 나타 내거나 또는 인간, 동물 림프구의 세포독성활성을 촉진시키는 것을 특징 으로 하는용도.
- 제 10항에 있어서,약학적 조성물은 면역결핍조건, 감염, 바이러스 혹은 곰팡이 감염과 같 은 전신감염 또는 종양성 질병의 치료 및 예방에 유용한 것을 특징으로 하는용도.
- 제 1항 내지 제 7항 중 어느 한 항에 개시된 펩티드를 암호화하는 핵산 염기서열.
- 제 1항 내지 제 7항 중 어느 한 항에 개시된 펩티드를 암호화하는 DNA 절편을 포함하며, 형질전환후 전기 펩티드를 발현할 수 있는 숙주세포내에서 전기 펩티드 발현에 적합한 벡터.
- 제 14항에 개시된 벡터에 의해 형질전환된 것을 특징으로 하는 숙주세포.
- 제 15항에 있어서,세균인 것을 특징으로 하는숙주세포.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU99127725/04A RU2172322C1 (ru) | 1999-12-27 | 1999-12-27 | Аллофероны-иммуномодулирующие пептиды |
RU99127725/04 | 1999-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010057591A true KR20010057591A (ko) | 2001-07-04 |
KR100394864B1 KR100394864B1 (ko) | 2003-08-19 |
Family
ID=20228810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0082812A KR100394864B1 (ko) | 1999-12-27 | 2000-12-27 | 알로페론-면역조절펩티드 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6692747B2 (ko) |
EP (1) | EP1114829B1 (ko) |
JP (1) | JP3564065B2 (ko) |
KR (1) | KR100394864B1 (ko) |
AT (1) | ATE362485T1 (ko) |
DE (1) | DE60034865T2 (ko) |
ES (1) | ES2283269T3 (ko) |
RU (1) | RU2172322C1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019240505A1 (ko) * | 2018-06-14 | 2019-12-19 | 주식회사 에이티파머 | 알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제 |
WO2020017845A1 (ko) * | 2018-07-17 | 2020-01-23 | 주식회사 에이티파머 | 알로페론을 포함하는 폐섬유증 치료용 조성물 |
WO2023146007A1 (ko) * | 2022-01-28 | 2023-08-03 | 엔케이메딕스 주식회사 | 알로페론을 포함하는 nk세포 배양용 조성물 및 이를 이용한 nk 세포 배양방법 |
WO2023146008A1 (ko) * | 2022-01-28 | 2023-08-03 | 엔케이메딕스 주식회사 | 알로페론으로 배양된 nk 세포를 함유하는 암 예방 또는 치료용 조성물 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796072B1 (fr) * | 1999-07-08 | 2003-09-19 | Centre Nat Rech Scient | Peptides anti-microbiens de mollusques |
RU2276988C2 (ru) * | 2004-01-15 | 2006-05-27 | Сергей Иванович Черныш | Антивирусное вещество |
RU2267496C2 (ru) * | 2004-01-15 | 2006-01-10 | Сергей Иванович Черныш | Противоопухолевые и антивирусные пептиды |
US7130534B1 (en) * | 2005-04-21 | 2006-10-31 | Agilent Technologies, Inc. | Gas chromatograph having a radiant oven for analytical devices |
EA009555B1 (ru) * | 2005-11-30 | 2008-02-28 | Сергей Иванович Черныш | Пептид, обладающий иммуномодулирующей активностью, и фармацевтическая композиция |
RU2338553C2 (ru) * | 2006-07-13 | 2008-11-20 | Общество с ограниченной ответственностью "Аллофарм, ООО "Аллофарм" | Средство для наружного применения, обладающее противовирусной активностью |
US20100150985A1 (en) * | 2008-04-24 | 2010-06-17 | George Just | Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same |
RU2470031C2 (ru) * | 2011-02-18 | 2012-12-20 | Общество с ограниченной ответственностью "Аллоферон" | Биологически активные пептидные комплексы |
US9499585B2 (en) | 2012-05-21 | 2016-11-22 | Alloferon Inc. | Bioactive peptide complexes |
KR20130138590A (ko) * | 2012-06-11 | 2013-12-19 | (주)알로텍 | 알로페론을 포함하는 항염증 약학적 조성물 및 화장료 조성물 |
KR101507101B1 (ko) | 2012-07-20 | 2015-03-30 | (주)알로텍 | 알로페론을 포함하는 항산화제 안정화 조성물 |
KR20140134957A (ko) * | 2013-05-15 | 2014-11-25 | (주)알로텍 | 알로페론을 포함하는 항암제 약학적 조성물 |
RU2560689C2 (ru) * | 2013-09-06 | 2015-08-20 | Общество с ограниченной ответственностью "Аллоферон" | Способ комплексной терапии преинвазивного и инвазивного рака шейки матки |
RU2014136096A (ru) * | 2014-09-05 | 2016-03-27 | Общество с ограниченной ответственностью "Аллоферон" | Лекарственное средство для лечения и профилактики заболеваний верхних и нижних дыхательных путей различной этиологии, его применение и метод лечения на его основе |
CN105203677A (zh) * | 2015-10-16 | 2015-12-30 | 江苏大学 | 一种利用生物质谱技术快速检测僵蚕蛋白质的方法 |
RU2667128C2 (ru) | 2016-12-29 | 2018-09-14 | Герман Петрович Беккер | Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе |
RU2673807C2 (ru) | 2017-05-05 | 2018-11-30 | Общество с ограниченной ответственностью "Научно-производственная фирма "ВЕРТА" | Средство, обладающее биоцидным действием |
RU2737852C2 (ru) * | 2017-12-28 | 2020-12-03 | Беккер Герман Петрович | Способ получения лекарственного средства на основе олигопептида аллоферона-1, имеющего противовирусную и иммуномодулирующую направленность, и лекарственное средство увеличенного срока хранения, полученное с его помощью |
RU2742565C1 (ru) * | 2019-12-29 | 2021-02-08 | Герман Петрович Беккер | Фармацевтическая композиция, содержащая биологически активные комплексы аллоферона с цинком, и способ ее получения |
KR20210106157A (ko) | 2020-02-20 | 2021-08-30 | 서울대학교산학협력단 | 알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제 |
KR20210106158A (ko) | 2020-02-20 | 2021-08-30 | 서울대학교산학협력단 | 알로페론을 포함하는 항암 치료 보조제 |
WO2022015194A1 (ru) * | 2020-07-15 | 2022-01-20 | Герман Петрович БЕККЕР | Противовирусное средство в форме суппозитория |
RU2742160C1 (ru) * | 2020-09-13 | 2021-02-02 | Общество с ограниченной ответственностью «Аллоферон» | Способ лечения алеутской болезни норок |
CN113234128B (zh) * | 2021-05-07 | 2023-03-07 | 庶安永康(厦门)健康产业有限公司 | 一种抗肿瘤活性多肽及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981003124A1 (en) | 1980-04-29 | 1981-11-12 | Pharmacia Ab | Polypeptide fraction from mussel for medical use |
DE3850180T2 (de) | 1987-07-01 | 1995-03-02 | Plant Genetic Systems Nv | Bakteriozide und/oder bakteriostatische Peptide, Verfahren zu ihrer Isolierung, Herstellung und Verwendung. |
ATE94073T1 (de) * | 1987-12-17 | 1993-09-15 | Thomas Dr Stiefel | Verwendung von haemocyaninen und arylphorinen zur beeinflussung des immmunsystems und behandlung von tumoren. |
GB8911333D0 (en) | 1989-05-17 | 1989-07-05 | Plant Genetic Systems Nv | New bacterial and/or bacteriostatic peptides,isolated from coleopteran insects |
US5346988A (en) | 1990-06-20 | 1994-09-13 | Tampa Bay Research Institute | Process for obtaining cellular protein having anti-HIV activity |
EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
US5804558A (en) | 1993-07-20 | 1998-09-08 | University Of California | Protegrins |
US5482711A (en) | 1993-08-25 | 1996-01-09 | Medenica; Rajko D. | Use of Nigella sativa to increase immune function |
DE9320586U1 (de) | 1993-10-11 | 1994-10-13 | Hgb Pharma Service Gmbh | Topische Formulierung eines solubilisierten Ginkgo-biloba-Extraktes |
IT1274592B (it) | 1994-08-05 | 1997-07-18 | Angela Turiano | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni |
AU5849796A (en) * | 1994-12-27 | 1996-08-07 | United Biomedical Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
US5714577A (en) | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
SE519350C2 (sv) | 1997-01-28 | 2003-02-18 | Anette Carlsson | Antibakteriellt protein med specifik effekt mot gram-negativa bakterier, farmaceutiskt aktiva fragment därav med samma specifika effekt, samt farmaceutisk komposition innehållande proteinet eller fragment därav |
WO2000029622A2 (en) * | 1998-11-17 | 2000-05-25 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
-
1999
- 1999-12-27 RU RU99127725/04A patent/RU2172322C1/ru active
-
2000
- 2000-12-12 DE DE60034865T patent/DE60034865T2/de not_active Expired - Lifetime
- 2000-12-12 AT AT00127166T patent/ATE362485T1/de not_active IP Right Cessation
- 2000-12-12 ES ES00127166T patent/ES2283269T3/es not_active Expired - Lifetime
- 2000-12-12 EP EP00127166A patent/EP1114829B1/en not_active Expired - Lifetime
- 2000-12-25 JP JP2000392281A patent/JP3564065B2/ja not_active Expired - Fee Related
- 2000-12-27 US US09/748,114 patent/US6692747B2/en not_active Expired - Lifetime
- 2000-12-27 KR KR10-2000-0082812A patent/KR100394864B1/ko active IP Right Grant
-
2003
- 2003-12-23 US US10/742,864 patent/US7462360B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019240505A1 (ko) * | 2018-06-14 | 2019-12-19 | 주식회사 에이티파머 | 알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제 |
WO2020017845A1 (ko) * | 2018-07-17 | 2020-01-23 | 주식회사 에이티파머 | 알로페론을 포함하는 폐섬유증 치료용 조성물 |
KR20200008950A (ko) * | 2018-07-17 | 2020-01-29 | 주식회사 에이티파머 | 알로페론을 포함하는 폐섬유증 치료용 조성물 |
WO2023146007A1 (ko) * | 2022-01-28 | 2023-08-03 | 엔케이메딕스 주식회사 | 알로페론을 포함하는 nk세포 배양용 조성물 및 이를 이용한 nk 세포 배양방법 |
WO2023146008A1 (ko) * | 2022-01-28 | 2023-08-03 | 엔케이메딕스 주식회사 | 알로페론으로 배양된 nk 세포를 함유하는 암 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
EP1114829B1 (en) | 2007-05-16 |
KR100394864B1 (ko) | 2003-08-19 |
RU2172322C1 (ru) | 2001-08-20 |
JP3564065B2 (ja) | 2004-09-08 |
ATE362485T1 (de) | 2007-06-15 |
DE60034865D1 (de) | 2007-06-28 |
EP1114829A3 (en) | 2001-07-18 |
US20040138137A1 (en) | 2004-07-15 |
JP2001348399A (ja) | 2001-12-18 |
EP1114829A2 (en) | 2001-07-11 |
US7462360B2 (en) | 2008-12-09 |
US20020151679A1 (en) | 2002-10-17 |
ES2283269T3 (es) | 2007-11-01 |
DE60034865T2 (de) | 2007-09-06 |
US6692747B2 (en) | 2004-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100394864B1 (ko) | 알로페론-면역조절펩티드 | |
EP1004595B1 (en) | Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents | |
JP2962555B2 (ja) | 溶菌ペプチドによる真核性病原体と新生物の抑制及び繊維芽細胞とリンパ球の刺激 | |
US6255282B1 (en) | Lytic peptides | |
Nagoshi et al. | Cloning and characterization of a LPS-regulatory gene having an LPS binding domain in kuruma prawn Marsupenaeus japonicus | |
Hajto et al. | Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients | |
Lowenberger et al. | Aedes aegypti: Induced Antibacterial Proteins Reduce the Establishment and Development ofBrugia malayi | |
Barr et al. | Activity of lytic peptides against intracellular Trypanosoma cruzi amastigotes in vitro and parasitemias in mice | |
EP1006124B1 (en) | Immunomodulatory materials from Calliphora vicina larvae, their preparation and use | |
Berg et al. | Bacterial infection induces a moth (Ephestia kuhniella) protein which has antigenic similarity to virus-like particle proteins of a parasitoid wasp (Venturia canescens) | |
KR100530125B1 (ko) | 개의난치성피부염의치료제및치료방법 | |
Hammar et al. | Induction of tubuloreticular structures in cultured human endothelial cells by recombinant interferon alfa and beta | |
EP1013763A1 (en) | CANINE INTERLEUKIN 18, CANINE INTERLEUKIN 1$g(b) CONVERTASE, DNA SEQUENCES ENCODING THE SAME, PROCESS FOR PRODUCING INTERLE UKIN 18, AND REMEDIES FOR CANINE IMMUNOLOGICAL DISEASES | |
CN111471094B (zh) | 一种抗微生物肽MSPiscidin-2、其编码基因及用途 | |
JPH1045618A (ja) | アポトーシス誘導剤 | |
RU2133616C1 (ru) | Иммунотропное средство | |
JP2000316585A (ja) | イヌインターフェロン−γ変異体、インターフェロン−γの製造法、イヌの難治性皮膚炎治療剤および治療方法 | |
Mulnix | Structure and regulation of expression of the lysozyme gene from the tobacco hornworm, Manduca sexta | |
EA004879B1 (ru) | Аллофероны-иммуномодулирующие пептиды | |
JP2001192396A (ja) | インターフェロン−γの活性を有するタンパク質の高純度製造法、イヌインターフェロン−γの活性を有する高純度タンパク質、イヌ疾病の治療剤およびイヌ疾病の治療方法 | |
JPH10306037A (ja) | イヌの難治性皮膚炎の治療剤および治療方法 | |
EA010578B1 (ru) | Антивирусное средство на основе гемолимфы насекомых подкласса pterigota |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120802 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20130617 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140806 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150803 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160721 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180724 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190731 Year of fee payment: 17 |